Michael Walters awarded Minnesota Partnership for Biotechnology and Medical Genomics grant

September 12, 2017

Using precision medicine study individual resistance to ER+ breast cancer inhibitors 
Researchers: Michael Walters, University of Minnesota; Dr. Liewei Wang, Mayo Clinic
Why do some women with estrogen receptor positive (ER+) breast cancer respond to the use of aromatase inhibitors – the first line of defense against the disease – but others don’t? ER+ cancer is the most common subtype of breast cancer, killing approximately 40,000 women annually. Researchers from the U of M and Mayo plan to use various techniques to study how and why DNA sequence differences between two individuals would affect response to aromatase inhibitors, and how clinicians can use this information to better individualize this kind of therapy.

Read more about the 'Minnesota Partnership' in Twin Cities Business


Categories: Health Sciences News